Bang J, Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review. Beulen L, Am J Obstet Gynecol. 21. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. NCHS data brief no. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. This is called a false-negative test result. 20. Information and tools for librarians about site license offerings. In: Wald N, Leck I, eds. We conducted the First- and Second-Trimester Evaluation of Risk (FASTER) Trial with the goal of providing direct comparative data on currently available screening approaches to Down's syndrome from a large population followed prospectively. Martin JA, Hamilton BE, Osterman MJK.
Your use of this information means that you agree to the Terms of Use. J Med Screen 2000;7:74-77[Erratum, J Med Screen 2000;7:168.]. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. Fully integrated screening (including measurement of nuchal translucency) yields the highest detection rates with the lowest false positive rates as compared with other forms of screening. Cell-free DNA analysis for noninvasive examination of trisomy. Series 20. Palomaki GE, Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Committee on Obstetric Practice, the American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine. The authorized source of trusted medical research and education for the Chinese-language medical community. 35. JAMA. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Midtrimester risk for chromosome abnormalities by maternal age. 1. The only exception may be in the case of multiple gestations (which were excluded from the present study), in which serum markers are difficult to interpret and nuchal-translucency measurements may allow for fetus-specific risk calculation. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. Estimates of risk based on gestational age-specific measurements will be more accurate than estimates based on measurements taken during the period from 11 through 13 weeks as a whole. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. First-trimester screening for Down's syndrome that includes the use of ultrasonography to assess nuchal translucency has become widespread since its introduction by Nicolaides and colleagues in the early 1990s.1-4 The largest U.S. study of first-trimester screening to date, involving 8514 pregnancies, reported a 79 percent detection rate at a 5 percent false positive rate.5 Second-trimester screening remains the most common approach to assessing the risk of Down's syndrome in the United States.6 When inhibin A is included in second-trimester quadruple screening, the estimated detection rate for Down's syndrome is 81 percent with a 5 percent false positive rate.7 However, little information is available on the comparative performance of these first- and second-trimester approaches. Navaratnam K, Second-trimester serum quadruple screening performed between 15 and 22 weeks' gestation detects 81% of trisomy 21 cases. This makes the veins below the band larger so it is easier to put a needle into the vein. 26. Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and the Society for Maternal-Fetal Medicine. The effect of a decision aid on informed decision-making in the era of non-invasive prenatal testing: a randomised controlled trial. Other screening programs that use first-trimester markers, such as integrated or sequential screening, will also be subject to degradation in performance if the first-trimester component is delayed until 13 weeks. 1. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. One hundred two approved ultrasonographers performed all nuchal-translucency evaluations. Carlson LM, Want to use this article elsewhere? Amniocentesis and chorionic villus sampling for prenatal diagnosis. Wald NJ, Hackshaw AK, George LM. Nicolaides KH, Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Gil MM, et al. Kuller JA, ); New York University School of Medicine, New York (I.E.T.-T.); the University of North Carolina Medical Center, Chapel Hill (H.M.W. Combinations of these tests include integrated or serum integrated, stepwise sequential, and contingent sequential screenings, all of which improve detection rates compared with each test alone. 2017;39(9):805–817. 175: ultrasound in pregnancy. A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. 2014;124(5):979–986. Am J Obstet Gynecol. But it doesn't guarantee that you will have a normal pregnancy or baby. The role of ultrasound in women who undergo cell-free DNA screening. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. Centers for Disease Control and Prevention. NCHS data brief no. Bang J, Brown CE. Measurements of biochemical markers were converted into multiples of the median (MoM) for gestational age, adjusted for maternal weight and race or ethnicity. We studied the performance of two types of integrated screening (involving measurement of markers at different gestational ages, but provision of a single result after all testing is complete)8: the fully integrated model, which incorporates first-trimester nuchal-translucency measurements, and the serum integrated model, which does not. Hemming K, 19. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. This study was conducted at 15 U.S. centers from October 1999 to December 2002. When the results are combined, these tests are known as the first-trimester screening. Chudova D, Dashe JS. Women with negative results return for quadruple screening, the results of which are interpreted without reference to the first-trimester results. Wald NJ, Watt HC, Hackshaw AK. The detection rates at various false positive rates and the false positive rates at various detection rates are summarized in Table 4. Fetal Aneuploidy: Screening and Diagnostic Testing. Accessed May 2019. The members of the FASTER Research Consortium are listed in the Appendix. Farrell RM, There are two serum screening tests available to all women; Combined First Trimester Screening (CFTS) and Second Trimester Maternal Serum Screening (2TMSS). 2015. #36: Prenatal aneuploidy screening using cell-free DNA. ); the Swedish Medical Center, Seattle (D.A.N. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing.